← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Regenerative Medical Solutions, Inc.
Chicago, IL
$3,838,950
Total funding
8
Grants
Funding over time
peak $1.5M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,838,950 · 8
By mechanism
R44$2,415,085 · 2
R43$1,148,881 · 5
R41$274,984 · 1
Investigators at Regenerative Medical Solutions, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells$915,136
R44 · FY2025 · DK
Human induced pluripotent stem cell-derived beta-cells for drug and toxicity testing$800,794
R44 · FY2016 · DK
Human induced pluripotent stem cell-derived beta-cells for drug and toxicity testing$699,155
R44 · FY2015 · DK
Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune tolerance$274,984
R41 · FY2022 · DK
Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells$259,578
R43 · FY2022 · DK
Development of a rapid and inexpensive luciferase-based high throughput screening assay to identify compounds that alter pancreatic β cell function$224,964
R43 · FY2016 · DK
Diabetes drug screening platforms using patient pancreatic islet-like cells generated from induced pluripotent stem cells$224,930
R43 · FY2016 · DK
Human Induced Pluripotent Stem Cell-Derived Beta-Cells for Drug and Toxicity Testing$222,020
R43 · FY2014 · DK
Engineered pancreatic endocrine cells that report beta cell toxicity for use in high throughput screening applications$217,389
R43 · FY2016 · DK